Best Weight Loss Medications for Men in 2026: GLP-1s and Beyond

Updated March 2026 • 12 min read • Medically reviewed content

Why Weight Loss Medications Work Differently for Men

Men and women don't gain weight the same way, and they don't lose it the same way either. Men carry a disproportionate amount of visceral fat — the metabolically active fat packed around organs in the abdominal cavity. This is the fat responsible for "beer bellies," and it's the fat most closely linked to heart disease, type 2 diabetes, and testosterone suppression.

The good news: visceral fat is also the fat that responds most aggressively to pharmacological intervention. In clinical trials, men consistently lose a higher percentage of body weight on GLP-1 medications than women, likely because of their higher baseline metabolic rate, greater visceral fat stores, and the testosterone-restoration cascade that weight loss triggers.

That testosterone piece matters. In men carrying significant excess weight, the aromatase enzyme in fat tissue converts testosterone to estradiol at an accelerated rate. The result is a vicious cycle — low testosterone makes it harder to build muscle, easier to store fat, and profoundly affects energy, mood, and sexual function. Weight loss medications that break this cycle don't just reduce body weight; they can fundamentally reset male metabolic health.

With that context, here's how every available weight loss medication stacks up for men in 2026, ranked by effectiveness.

Tier 1: GLP-1 Receptor Agonists — The Standard of Care

Semaglutide (Ozempic / Wegovy / Compounded)

Semaglutide changed everything. Originally approved for type 2 diabetes (as Ozempic), the higher-dose formulation (Wegovy, 2.4mg weekly) became the first GLP-1 medication approved specifically for weight management. In the STEP 1 trial, participants lost an average of 14.9% of body weight over 68 weeks.

For men specifically, semaglutide offers several distinct advantages. The reduction in visceral fat triggers measurable testosterone increases — data presented at ENDO 2025 showed testosterone normalization in 77% of men with obesity-related hypogonadism after 12 months on semaglutide. The cardiovascular benefits are equally compelling: the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events, which is particularly relevant for men (who face higher cardiovascular risk at every age).

In 2026, most men access semaglutide through telehealth providers offering compounded formulations, which typically run $200–$400/month compared to $1,000+/month for brand-name Wegovy without insurance. The FDA's evolving regulatory stance on compounded semaglutide is something every man should be tracking — read our full regulatory breakdown here.

Tirzepatide (Mounjaro / Zepbound / Compounded)

Tirzepatide is the dual GIP/GLP-1 receptor agonist that's generating the most excitement in obesity medicine. By activating two incretin pathways instead of one, tirzepatide has demonstrated even greater weight loss than semaglutide in head-to-head comparisons. The SURMOUNT-1 trial showed average weight loss of 22.5% at the highest dose — roughly 50–60 lbs for a man starting at 260 lbs.

For men, tirzepatide may have a meaningful muscle-preservation advantage. Early data suggests the GIP receptor activation promotes more favorable body composition changes, with a higher ratio of fat loss to lean mass loss compared to semaglutide alone. For men who lift or want to preserve strength during weight loss, that differential matters — and it's why our semaglutide vs tirzepatide comparison consistently recommends tirzepatide for fitness-conscious men.

Compounded tirzepatide is available through several telehealth providers at $250–$450/month, though availability can be less consistent than semaglutide. As of early 2026, Eli Lilly has been more aggressive than Novo Nordisk in challenging compounding pharmacies, so pricing and access may shift through the year.

Oral Semaglutide (Rybelsus / Upcoming Higher-Dose)

For men who'd rather not inject, oral semaglutide is increasingly viable. Rybelsus (the current oral formulation at 3mg, 7mg, and 14mg) was approved for type 2 diabetes and produces modest weight loss. But the real game-changer is the higher-dose oral semaglutide (25mg and 50mg) that showed weight loss comparable to injectable semaglutide in clinical trials. Novo Nordisk has sought regulatory approval for the 25mg/50mg dose, bringing injectable-level results in pill form.

Several telehealth providers now offer oral semaglutide for men who prefer it. Read our full oral semaglutide guide for the latest pricing and availability.

Tier 2: Phentermine and Phentermine Combinations

Phentermine (Adipex-P, Lomaira)

Phentermine is the oldest FDA-approved weight loss drug still in active use, and it remains the most commonly prescribed. It's a sympathomimetic amine — essentially a stimulant that suppresses appetite and increases energy expenditure. Average weight loss is 5–7% of body weight over 12 weeks.

For men, phentermine has a specific niche: it's cheap ($15–$40/month generic), it works fast (appetite suppression kicks in within days, not weeks), and it pairs well with a new exercise program because of the energy boost. The downsides are significant, though. It's only approved for short-term use (12 weeks), it raises blood pressure and heart rate, it can cause insomnia, and it has abuse potential. Men with any cardiovascular history should avoid it entirely.

Phentermine works best as a bridge medication — something to start on while waiting for GLP-1 access or titrating up to full dose. Many telehealth providers offer it at a fraction of GLP-1 costs.

Phentermine/Topiramate (Qsymia)

Qsymia combines phentermine with topiramate (an anticonvulsant that also suppresses appetite) in a single pill. The combination produces 8–10% average body weight loss — better than either drug alone. It's the most effective non-GLP-1 medication on the market.

Men should be aware that topiramate can cause cognitive dulling ("brain fog"), kidney stones (which men are already more prone to), and paresthesia (tingling in hands and feet). The cognitive effects are dose-dependent and usually mild, but for men in demanding intellectual roles, they can be meaningful.

Tier 3: Contrave (Naltrexone/Bupropion)

Contrave combines naltrexone (an opioid antagonist used in addiction medicine) with bupropion (an antidepressant and smoking cessation aid). Together, they target the brain's reward system and hypothalamic appetite centers. Average weight loss is 5–8% of body weight.

Contrave occupies an interesting niche for men. Bupropion is one of the few antidepressants that doesn't cause sexual dysfunction — it can actually improve libido and function. If you're a man dealing with weight gain, mild depression, and decreased sex drive, Contrave might address all three simultaneously. It's also effective for men whose weight gain is driven by food-as-reward patterns, emotional eating, or alcohol-adjacent eating (naltrexone reduces the pleasure response to alcohol too).

The cost is moderate — around $100–$200/month depending on insurance. Side effects include nausea (especially during the first 2 weeks), headaches, constipation, and insomnia. It's contraindicated in men with seizure disorders or heavy alcohol use.

Tier 4: Metformin (Off-Label)

Metformin isn't FDA-approved for weight loss, but it's been used off-label for decades. It's an insulin sensitizer — it reduces hepatic glucose production and improves insulin sensitivity, which can produce modest weight loss (3–5% of body weight) particularly in insulin-resistant men.

The appeal for men is the price (as low as $4/month generic) and the emerging longevity data. Metformin is being studied in the TAME trial (Targeting Aging with Metformin) for potential anti-aging benefits, and observational data suggests metformin users have lower all-cause mortality than even non-diabetic controls.

For men with prediabetes or insulin resistance who can't access or afford GLP-1 medications, metformin is a rational first step. It's also commonly combined with GLP-1 agonists for additive effects. The main side effect is GI distress (diarrhea, bloating), which usually resolves within 2–4 weeks. Extended-release formulations are better tolerated.

Tier 5: Orlistat (Alli / Xenical)

Orlistat works by blocking fat absorption in the gut — roughly 30% of dietary fat passes through undigested. Average weight loss is 3–5% of body weight, making it the least effective prescription option.

Most men find the side effects intolerable. Unabsorbed fat has to go somewhere, and the result is oily stools, flatulence with discharge, fecal urgency, and occasional fecal incontinence. For men, this is typically a non-starter. The only scenario where orlistat makes sense is for men who specifically want an OTC option (Alli 60mg) and have tried nothing else. Otherwise, virtually every other medication on this list produces better results with fewer lifestyle-disrupting side effects.

Coming Soon: The Next Generation

Orforglipron (Oral GLP-1, Eli Lilly)

Orforglipron is the most anticipated weight loss drug in the pipeline. It's a non-peptide oral GLP-1 agonist — meaning it can be taken as a daily pill without the absorption limitations of oral semaglutide (which requires fasting, no other medications, and sitting upright for 30 minutes). Eli Lilly submitted the NDA in late 2025, and approval could come in 2026.

Phase 3 data showed approximately 14% body weight loss — not quite tirzepatide territory, but in a convenient daily pill with no injection anxiety. For men who've avoided GLP-1 treatment because they don't want to inject, orforglipron could be the tipping point. Read our full pipeline coverage here.

CagriSema (Amylin + Semaglutide, Novo Nordisk)

CagriSema combines semaglutide with cagrilintide (an amylin analog) for dual-pathway appetite suppression. The REDEFINE-2 trial showed 24.6% body weight loss — the highest of any obesity medication ever tested. If approved, CagriSema would set a new ceiling for pharmacological weight loss.

Retatrutide (Triple Agonist, Eli Lilly)

Retatrutide activates three receptors — GLP-1, GIP, and glucagon — for what may be the most powerful anti-obesity mechanism yet tested. Phase 2 data showed up to 24.2% weight loss at 48 weeks, with the glucagon receptor activation providing additional metabolic benefits including improved liver fat reduction. Phase 3 trials are ongoing.

The Complete Comparison: Every Medication Ranked for Men

*Compounded pricing through telehealth providers. Brand-name GLP-1 pricing without insurance: $900–$1,400+/month.

Where to Get Started: Top GLP-1 Providers for Men in 2026

If you've decided a GLP-1 agonist is right for you — and for most overweight men, the evidence strongly supports it — here are the providers we recommend based on pricing, male-specific protocols, and medication quality.

For a deeper dive on every provider with detailed comparison ratings, see our full GLP-1 provider rankings for men.

How to Decide Which Medication Is Right for You

The decision tree for men in 2026 is more straightforward than it's ever been:

Whatever you choose, the evidence is clear: for men carrying excess weight, pharmacological intervention combined with lifestyle modification produces dramatically better outcomes than diet and exercise alone. The medications listed above aren't shortcuts — they're tools that correct the neurochemical and hormonal imbalances that make sustained weight loss nearly impossible for many men.

For the full picture on GLP-1 treatment specifically, start with our flagship GLP-1 guide for men — or for a broader look at weight loss medications across all demographics, visit our partner site HealthyWeightMeds.com.